KR20090110778A - Pharmaceutical composition comprising the extract of sea tangle for preventing and treating cataract and food composition comprising the extract of sea tangle for preventing and improving cataract - Google Patents

Abstract

PURPOSE: A pharmaceutical composition and a food composition for preventing and treating cataract containing sea tangle extract are provided to promote glutathione synthesis and increase the concentration of glutathione peroxidase in a crystalline lens. CONSTITUTION: A pharmaceutical composition and a food composition for preventing and treating cataract contain sea tangle extract. The sea tangle extract contains glutamate, glycine, or cystein. The sea tangle extract further contains magnesium. The composition is used for oral or parenteral administration. The sea tangle extract is isolated through hot water extraction. Ferric ion component is removed from the sea tangle extract.

Description

Pharmaceutical composition comprising the extract of sea tangle for preventing and treating cataract and food composition comprising the extract of sea tangle for preventing and improving cataract}

The present invention relates to a pharmaceutical composition for preventing and treating cataracts containing kelp extract, and more particularly, to a cataract prevention and treatment composition including glutamate, glycine and cysteine extracted from kelp and cataract prevention containing the kelp extract. And it relates to a food composition for improvement.

When a person reaches a certain age, the lens of the eye (the organ corresponding to the lens of the camera) becomes hard and cloudy, making it difficult for light to pass through and gradually blurring the vision, which is cataract. In particular, when oxidative stress caused by free radicals acts on the eye, the protein of the lens may be oxidized to cause cataracts, and the elderly may decrease the ability of oxidative stress such as free radicals to increase the possibility of cataracts. The initial incidence of cataracts is about 60% in the 60s and 80% in the 70s, and most occur in the 80s. Recently, the incidence rate of cataracts is increasing in various 30s and 40s.

Cataracts can cause fog or appear cloudy, blurred vision, glare and overlapping objects. Once cataracts occur, the use of eye drops that inhibit progression or surgical removal of the cataract in which the cataract develops and the implantation of intraocular lens are currently being performed. In the case of the surgical treatment of the above treatments, a lot of developments in the last decade, the method of treating cataracts by non-surgical methods such as eye drops or oral treatment such as eye drops is still a weak effect.

The causes of cataracts are various, such as oxidative stress and protein aggregation, but it has been reported that in patients with cataracts, the amount of glutathione (GSH) in the lens is reduced, and with the reduction of GSH, protection against oxidative disorders is increased. It is thought that the lens is turbid because it is lowered. Glutathione is an antioxidant widely distributed in vivo, and its chemical name is represented by γ-L-glutamyl-L-cysteinyl-glycine (γ-L-glutamyl-L-cysteinyl-glycine). The glutathione combines two molecules during oxidation to form disulfide bonds (GSSH). In the case of reduced form glutathione, the glutathione is a substrate of glutathione peroxidase. Mitch acts to inhibit oxidative disorders.

Therefore, when excessive oxidative stress is applied, glutathione in the living body is consumed / depleted, making it difficult to maintain normal cell function, and glutathione agents have been used to treat pathologies caused by lowering the intracellular concentration of glutathione. For example, Korean Patent Laid-Open Publication No. 1990-2770 discloses an eye drop containing an oxidized glutathione used for cataract treatment, but has a disadvantage in that its effect is inadequate because the molecular weight is not properly absorbed.

In addition, U.S. Patent No. 5110796 discloses a cataract prevention and treatment agent containing glutathione monoalkyl ester, but this also has a problem that the effect is weak because the absorption is not large because the molecular weight is large.

Therefore, the first problem to be solved by the present invention is prepared by using a natural extract and can be effectively prevented cataracts by increasing the concentration of glutathione and glutathione peroxidase in the eye even when used as a subcutaneous injection, oral administration or eye drops. It is to provide a pharmaceutical composition for the prevention and treatment of cataracts containing the kelp extract.

The second problem to be solved by the present invention is to provide a food composition for preventing and improving cataracts containing the kelp extract.

The third problem to be solved by the present invention is to provide a method for preparing the kelp extract.

The present invention to solve the first problem,

It provides a pharmaceutical composition for the prevention and treatment of cataracts containing kelp extract as an active ingredient.

According to one embodiment of the present invention, the kelp extract may be one containing glutamate, glycine and cysteine.

It is also preferred that the glutamate, glycine and cysteine form glutathione in the lens and increase the intracellular lens concentration of glutathione peroxidase.

In addition, the kelp extract preferably further comprises magnesium.

According to another embodiment of the present invention, the composition may be oral or parenteral, and when the composition is an injection, the dosage of the injection is preferably 10 to 200 mg / kg bwt.

According to another embodiment of the present invention, the kelp extract may be a hot water extract.

According to a preferred embodiment of the present invention, the kelp extract may be an iron ion component is removed after extraction, which is preferably using an ion exchange resin.

The present invention to solve the second problem,

It provides a food composition for preventing and improving cataracts containing kelp extract as an active ingredient.

According to one embodiment of the present invention, the kelp extract may be one containing glutamate, glycine and cysteine.

The glutamate, glycine and cysteine preferably form glutathione in the lens and increase the concentration in the lens of glutathione peroxidase.

In addition, the kelp extract preferably further comprises magnesium.

According to another embodiment of the present invention, the kelp extract may be a hot water extract, it is preferable that the iron ion component is removed using an ion exchange resin.

The present invention to solve the third problem,

An extract preparation step of extracting kelp using any one extraction solvent selected from the group consisting of water, methanol, ethanol, butanol, acetone, hexane, chloroform, dichloromethane, ethyl acetate, and mixtures thereof; And

It provides a method for producing kelp extract comprising an iron ion removal step of removing the iron ion component by using an ion exchange resin to the extract obtained in the extract manufacturing step.

According to one embodiment of the present invention, the extraction solvent is preferably water, and may further comprise the step of adding magnesium ions after the iron ion removal step.

Since it promotes the synthesis of glutathione in the lens according to the present invention and increases the concentration of glutathione peroxidase in the lens, it is effective in preventing and inhibiting the occurrence of cataract due to oxidative stress, and the effective concentration prevents cataract. And it can play a role as a therapeutic agent, especially in the removal of iron ions has the advantage that the cataract prevention and treatment effect is more excellent.

Hereinafter, the present invention will be described in more detail.

The pharmaceutical composition for the prevention and treatment of cataracts containing kelp extract according to the present invention as an active ingredient is prepared using natural extracts and is non-toxic to peroxides such as hydrogen peroxide or lipid peroxide by increasing the concentration of glutathione and glutathione peroxidase in the eye. It is characterized in that it can effectively prevent and treat cataracts.

Oxygen can be a state that is easy to acquire electrons according to the electron arrangement can be a powerful oxidant. In the intracellular respiration process, oxygen molecules are reduced by four electrons and converted into water. However, when oxygen molecules are incompletely reduced, they become powerful oxidants, and they are called Reactive Oxygen Species (ROS). Oxygen molecules reduced by one, two or three electrons are called O ² O (superoxide radical anion), H ₂ O ₂ (hydrogen peroxide) or OH ^˙ (hydroxyl radical), respectively. .

The ROS produced in cells attack three kinds of physiological macromolecules such as lipids, nucleic acids, and proteins, and fats become rancid as a result of lipid peroxidation chain (cyclic endoperoxide) and unsaturated. They produce aldehydes that can cause mutations or inactivate enzymes, and they can also be immobilized to cross-link proteins and nucleic acids. Lipid peroxidation also decreases the fluidity of cell membranes and reduces the function of membrane proteins. Oxidative damage to nucleic acids creates adducts of bases or sugars, destroys single or double helices, and cross-links with other molecules. On the other hand, when the protein is oxidized, oxidative addition of amino acids, protein-protein crosslinking, peptide cleavage, and the like may be caused.

In particular, in the case of cataracts, it is known that the enzyme system is inactivated, the protein aggregates, and the discoloration of the lens occurs due to oxidative stress caused by the accumulation of hydrogen peroxide.

Therefore, the ROS removal system is operating in the cell in order to prevent such accumulation and harmful oxidation of ROS. For example, since a component containing a thiol group (cysteine residue of glutathione) has a reducing power, oxidative ability of ROS is removed by providing electrons to the ROS. The content of glutathione in the cell is about 5-10 mM, which varies slightly depending on the site of the cell. In cataracts, exposure to oxidative stress decreases the concentration of glutathione in the eye, preventing the antioxidant system from working properly. Formula 1 shows the structure of glutathione, and Formula 2 shows the structure of three amino acids, Gly (glycine), Glu (glutamate), and Cys (cysteine).

As can be seen in Formulas 1 and 2, glutathione is a tripeptide consisting of three amino acids, Gly (glycine), Glu (glutamate), and Cys (cysteine). Scheme 1 shows a synthesis cycle of glutathione. 2 shows the synthesis and metabolic cycles of glutathione.

The mechanism of action of the pharmaceutical composition for preventing and improving cataracts according to the present invention is believed to be due to the fact that the active ingredient contained in the kelp extract promotes the synthesis of glutathione in the lens. As already mentioned, it is difficult to supply glutathione into the eye or lens because glutathione itself has a high molecular weight and cannot be absorbed into cells. However, in the present invention, glutamate, glycine, and cysteine contained in the kelp extract form glutathione through covalent bonds in the lens, and thus, the concentration of glutathione peroxidase is also improved. The glutathione peroxidase is an enzyme present in the body and has an activity of extinguishing hydrogen peroxide. Since glutathione is used as a substrate, the amount of glutathione present in the body greatly affects the enzyme activity of the glutathione peroxidase.

Referring to Scheme 1, glutamate, glycine and cysteine bind to γ-glutamylcysteine synthetase (EC 6.3.2.2.) And glutathione synthetase in synthesizing glutathione. Among them, the γ-glutamylcysteine synthase is the first step and the rate-limiting step of glutathione biosynthesis to synthesize γ-glutamylcysteine from glutamate and cysteine in the presence of ATP, It is an enzyme of about 68 kDa that plays a decisive role in the synthesis of glutathione in organisms, which catalyzes the presence of magnesium, and since the kelp extract contains magnesium, it promotes the enzyme action of the γ-glutamylcysteine synthase. In the kelp extract Since the amount of magnesium contained is usually 0.5%, it is preferable to further add magnesium to the composition for preventing and treating cataracts according to the present invention, and magnesium may be added in the form of an ionic compound.

When the composition for preventing and treating cataracts according to the present invention is administered, the concentration of glutathione and glutathione peroxidase in the lens is increased, thereby reducing hydrogen peroxide and hydroxy radicals, thereby preventing cataracts and improving symptoms. In addition, kelp contains fucoidan, which means sulfated polysaccharides contained in the slippery slime contained in brown algae, which prevents seaweeds from invading the waves or rocks and prevents bacterial invasion. It is a bioactive substance that is produced for. These fucoidans are U-fucoidan, F-fucoidan, G-fucoidan, and three types, and because of their excellent antioxidant function, it is considered that the composition according to the present invention can enhance the preventive effect of cataract.

Kelp extract used in the present invention may be a crude extract, a polar solvent soluble extract, may be a non-polar solvent soluble extract. The crude extracts include those extracted from lower alcohols such as water, ethanol and methanol, or mixed solvents thereof. The polar solvent soluble extract means extracted from acetone, butanol, ethanol, methanol or water with a polar solvent selected, and a nonpolar solvent. The soluble extract includes a nonpolar solvent selected from hexane, chloroform, dichloromethane or ethyl acetate, preferably extracted with ethyl acetate.

The extraction method is not particularly limited as long as it can efficiently extract glutamate, glycine and cysteine, it is preferable to simply extract by hot water extraction. The pressure at the time of extraction may be any of normal pressure, pressure, and reduced pressure. In addition, an extraction method using a polar solvent is preferred to facilitate the extraction of magnesium ions, and for this reason, the most preferred extraction solvent is water.

On the other hand, the composition for preventing and improving cataract according to the present invention is more preferably removed from the iron ions contained in the extract after extracting the kelp extract. The reason for this is that antioxidants such as vitamin C may act as oxidants in the presence of iron ions, and H ₂ O ₂ in the cells may form hydroxy radicals in the presence of Fe ²⁺ ions. This is to prevent. The method of removing the iron ions can be used without particular limitation as long as it is commonly known in the art, for example, by adsorbing iron ions using silica, chelate bond with iron ions. The method using the chelate ion exchange resin which existed, etc. are mentioned. As said chelate ion exchange resin, styrene / divinylbenzene chelate ion exchange resin, the chelate ion exchange resin which has a paired imino diacetate functional group, or an imino diacetic acid functional group, etc. are mentioned, for example, Rom and AMBERLITE® IRC 718 (sodium form) commercially available from Haas Company or Chelex®20 or Chelex®100 (sodium form) commercially available from Biorad Company can be used.

Meanwhile, when iron ions are removed using the chelate ion exchange resin as described above, magnesium ions may also be removed, and thus, magnesium is preferably added after the iron ion removal process.

The pharmaceutical compositions according to the invention may be administered in various formulations, oral and parenteral, in actual clinical administration. Solid preparations for oral administration include tablets, pills, powders, granules and capsules, and the like, which may be at least one excipient such as starch, calcium carbonate, sucrose, lactose and gelatin, etc. Can be prepared by mixing. In addition to simple excipients, glidants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, solvents, emulsions, and syrups. In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances and preservatives are available. And the like. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and the like. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. Dosage units may, for example, contain 1, 2, 3 or 4 times the individual dosage or may contain 1/2, 1/3 or 1/4 times. The individual dosage preferably contains an amount in which the effective drug is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dose.

In the pharmaceutical composition, the effective dose of kelp extract is less than 200 mg / kg body weight, more preferably 10 to 150 mg / kg body weight, but the dosage level for a particular patient is determined by the patient's weight, age, It may vary depending on sex, health condition, diet, time of administration, method of administration, rate of excretion, severity of disease, and the like.

In the case of the food composition according to the present invention, the kelp extract may be added as it is or may be appropriately used in accordance with conventional methods with other food or food ingredients. The amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment), and may be used according to the effective dose of the pharmaceutical composition, but for health and hygiene purposes or for health control purposes. In the case of long-term intake to be less than the above range, the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

On the other hand, there is no particular limitation on the type of food, and may include nutritional supplements, functional foods, health foods or beauty foods, for example, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen And other dairy products including noodles, gums, ice creams, various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes.

Hereinafter, the present invention will be described in more detail with reference to preferred examples, but the present invention is not limited thereto.

Example 1

Kelp extract and Of stock solution  Produce

3L of distilled water was added to 500 g of kelp cultivated in Ongjin-gun, Incheon, and hot water was extracted and filtered at 100 ° C. for 4 hours, and the extract was lyophilized. The lyophilized extract was dissolved in saline to prepare 25, 50, 100 and 200 mg / ml of stock solution, respectively.

Example 2

Analysis of Amino Acids and Their Contents in Kelp Extracts

The analysis was performed by the Korea Research Institute of Basic Science and Technology. Take 10.38 mg of the extract sample, hydrolyze and PITC (Phenyl isothiocyanate) labeling using PICO-tag method, take 10 μl of the sample, load it on HPLC, and chromatogram It was obtained, and the results are shown in Table 1 below.

amino acid Content (pmol) Asp 12943.780 Glu 39309.887 Cys2 235.162 Gly 9862.749 Ser 5864.743 His 2170.835 Arg 2818.017 Thr 6370.933 Ala 19275.175 Pro 7635.962 Tyr 1915.901 Val 7717.756 Met 2788.048 Ile 4998.947 Leu 8667.008 Lys 4834.982

The pmol means the content of amino acid per 0.259 mg of the sample.

Referring to Table 1, there are various amino acids in the kelp extract, including among them, glutamic acid, glycine and cysteine (Cys2), which can form glutathione in the lens.

Example 3

Measurement of cataract suppression effect

Cataracts were induced by subcutaneous injection of 15 μmol / kg bwt of sodium selenite on the 11th day of life in the remaining 6 groups except the normal group (group 1). The control group (Group 2) is physiological saline, Group 3 is Ascorbic acid (1000mg / kg bwt), Next, using the kelp extract stock solution prepared in Example 1 Group 4 25mg / kg bwt, Group 5 50mg / kg bwt, group 6 was administered 100mg / kg bwt, group 7 was administered 200mg / kg bwt intraperitoneally from the third day after birth. Cataract incidence was recorded with Slit lamp photo (FS-3, Nikon, Japan) on the 4th day of sodium selenite injection, followed by 1, 2, and 3 weeks of cataract, respectively. The imaging results for (OD) and left eye (OS) are shown in FIGS. 1 to 7 and the degree of cataract development is shown in Table 2 below.

group Cataract outbreak population Group 1 0/10 Group 2 8/10 Group 3 4/10 4th group 3/10 5 groups 2/10 6 groups 1/10 Group 7 6/10

Referring to FIGS. 1 to 7 and Table 2, the average cataract incidence after 3 weeks of sodium selenite injection was 0/10 normal group, 8/10 control group, 4/10 group 3, 3/10 group 4 3, 4, 5, 6, 7 groups showed lower incidence, especially in group 6, with 2/10 animals in group 5, 1/10 animals in group 6, and 6/10 animals in group 7. Was low (p <0.05). Groups 4, 5 and 6 (p <0.05) showed a significant difference from the control group (p <0.05). Therefore, the dosage of the injection when the kelp extract is used as an injection is preferably 10 to 200 mg / kg bwt, more preferably 25 to 100 mg / kg bwt. When the dose is less than 10 mg / kg bwt, the effect is weak, and when it exceeds 200 mg / kg bwt, the incidence of cataract may increase again due to the effect of iron ions is not preferable. All cataracts developed showed central dense nucleosclerosis.

Example 4

Lens tissue MDA , SOD  And GPx  Measurement of concentration

After capturing the degree of cataract formation of the lens, the eye was taken out, the lens and the water repellent were collected and centrifuged, followed by Malondialdehyde (MDA), Superoxide dismutase (SOD) and glutathione peroxidase (GPx) of the lens tissue. ) Was measured by ELISA method and the results are shown in Table 3.

 group MDA (μmol / l) GPx (nmol / min / ml) SOD (U / ml) Group 1 <0.01 93 32.20 Group 2 <0.01 207 38.15 Group 3 0.81 210 50.10 5 groups 0.60 230 44.75 6 groups  <0.01 289 52.95 Group 7 0.05 241 50.10

Referring to Table 3, the concentration of glutathione peroxidase was significantly increased in groups 5, 6, and 7, which is believed to be due to the increase in the concentration of glutathione in the lens, so that the composition according to the present invention It can be said that it promotes the synthesis of glutathione within, and increases the concentration of glutathione peroxidase.

Example 5

Determination of Cataract Inhibitory Effect of Extracts from Iron Ions

Iron using ion exchange chromatography employing Amberlite XAD-4 (manufactured by Rohm & Haas) resin impregnated with 2-methyl-8-hydroxyquinoline (MHQ) as an ion exchange resin to the kelp extract prepared in Example 1 After removing the ions and lyophilized, the lyophilized extract was dissolved in saline to prepare a 200 mg / ml stock solution. The content of iron ions was analyzed by ICP-AEA, and about 40 ppm of iron ions were present in the kelp extract before the iron ions were removed, but it was confirmed that the iron ions were almost absent when the iron ions were removed.

Cataracts were induced by subcutaneous injection of 15 μmol / kg bwt of sodium selenite at 11 days of age in each group. In the control group (group 1), physiological saline solution, group 2, 50 mg / kg bwt of the kelp extract stock solution prepared in Example 1, and finally, in the case of group 3, the kelp extract stock solution from which iron ions were removed was 50 mg / kg bwt, the same amount as group 2, was administered intraperitoneally from day 3 after birth. Next, 4 days after the sodium selenite injection, the degree of cataract was photographed by Slit lamp photo (FS-3, Nikon, Japan). After 3 weeks, the degree of cataract was photographed, respectively. .

group Cataract outbreak population Group 1 9/10 Group 2 2/10 Group 3 1/10

Referring to the above results, the incidence rate of cataract in group 2 was 20%, whereas in group 3, the incidence rate was low as 10%, which is an effect of the iron ions removed.

Formulation Example 1

Manufacture of tablets

200 mg of dry extract obtained in Example 1

100 mg lactose

Cornstarch 100mg

Magnesium stearate proper amount

The tablets were prepared by mixing the above components and tableting according to a conventional method for producing tablets.

Formulation Example 2

Preparation of Injectables

100 mg of dry extract obtained in Example 1

Sodium Metabisulfite 3.0mg

Methylparaben 0.8mg

Propylparaben 0.1mg

Appropriate sterile distilled water for injection

The above ingredients were mixed and adjusted to 2 ml by a conventional method, and then filled into 2 ml ampoules and sterilized to prepare an injection.

Formulation Example 3

Preparation of Capsules

100 mg of dry extract obtained in Example 1

50 mg lactose

Cornstarch 50mg

Talc 2mg

Magnesium stearate proper amount

The capsules were prepared by mixing the above components and filling the gelatin capsules according to a conventional method for preparing capsules.

Formulation Example 4

Health drink  Produce

200 mg of dry extract obtained in Example 1

20g liquid fructose

20g oligosaccharide

Citric acid

Lemon flavor

Here, purified water was mixed to make a syrup, and the syrup was heat sterilized and then mixed with cooling water to prepare a healthy beverage.

1 is a slit lamp photograph of eyeballs of group 1 not administered with anything.

Figure 2 is a slit lamp photograph of the eyes of the group injected with physiological saline after subcutaneous injection of sodium selenite 15μmol / kg bwt induced cataracts.

Figure 3 is a slit lamp photograph of the eyes of the group injected with ascorbic acid 1000mg / kg bwt after subcutaneous injection of sodium selenite 15μmol / kg bwt induced cataract.

Figure 4 is a slit lamp photograph of the eyes of the group injected with 25 mg / kg bwt kelp extract according to the invention after subcutaneous injection of sodium selenite 15μmol / kg bwt induced cataract.

Figure 5 is a slit lamp photograph of the eyes of the group injected with 50 mg / kg bwt kelp extract according to the invention after subcutaneous injection of sodium selenite 15μmol / kg bwt induced cataract.

Figure 6 is a slit lamp photograph of the eyes of the group injected with kelp extract 100mg / kg bwt according to the present invention after subcutaneous injection of sodium selenite 15μmol / kg bwt induced cataract.

Figure 7 is a slit lamp photograph of the eyes of the group injected with 200mg / kg bwt kelp extract according to the present invention after subcutaneous injection of sodium selenite 15μmol / kg bwt induced cataract.

Claims (18)

A pharmaceutical composition for the prevention and treatment of cataracts containing kelp extract as an active ingredient. The method of claim 1, The kelp extract is a pharmaceutical composition for cataract prevention and treatment comprising glutamate, glycine and cysteine. The method of claim 2, The glutamate, glycine and cysteine form glutathione in the eye and increase the intraocular concentration of glutathione peroxidase, characterized in that the composition for preventing and treating cataracts. The method of claim 1, The kelp extract is a pharmaceutical composition for cataract prevention and treatment, characterized in that it further comprises magnesium. The method of claim 1, Cataract prevention and treatment pharmaceutical composition, characterized in that the composition for oral or parenteral use. The method of claim 1, If the composition is an injection, the dosage of the injection is a pharmaceutical composition for the prevention and treatment of cataract, characterized in that 10 ~ 200mg / kg bwt. The method of claim 1, The kelp extract is a pharmaceutical composition for cataract prevention and treatment, characterized in that the hot water extract. The method according to any one of claims 1 to 7, The kelp extract is a pharmaceutical composition for cataract prevention and treatment, characterized in that the iron ion component is removed after extraction. The method of claim 8, The kelp extract is a pharmaceutical composition for cataract prevention and treatment, characterized in that the iron ion component is removed using an ion exchange resin. Cataract prevention and improvement food composition containing kelp extract as an active ingredient. The method of claim 10, The kelp extract is a food composition for cataract prevention and improvement, comprising glutamate, glycine and cysteine. The method of claim 11, The glutamate, glycine and cysteine form glutathione in the lens and increase the concentration of glutathione peroxidase in the lens, characterized in that the food composition for cataract prevention and improvement. The method of claim 10, The kelp extract is a food composition for cataract prevention and improvement, further comprising magnesium. The method of claim 10, The kelp extract is a food composition for cataract prevention and improvement, characterized in that the hot water extract. The method according to any one of claims 10 to 14, The kelp extract is a food composition for cataract prevention and improvement, characterized in that the iron ion component is removed using an ion exchange resin. (a) an extract preparation step of extracting kelp using any one extraction solvent selected from the group consisting of water, methanol, ethanol, butanol, acetone, hexane, chloroform, dichloromethane, ethyl acetate, and mixtures thereof; And (B) a method for producing kelp extract comprising an iron ion removal step of removing the iron ion component using an ion exchange resin in the extract obtained in the extract preparation step. The method of claim 16, The extraction solvent is a method for producing kelp extract, characterized in that the water. The method of claim 16, After the step (b), the method for producing kelp extract, characterized in that it comprises the step of adding magnesium.

Images